{"id":"W3004590183","doi":"10.1200/jco.2020.38.4_suppl.639","title":"A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Neutropenia; Gastroenterology; Clinical endpoint; Hazard ratio; PARP inhibitor; Surgery; Oncology; Randomized controlled trial; Cancer; Toxicity; Confidence interval; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002109627,0.002072833,0.002073346,0.0004669037,0.0004905292,0.001333411,0.001274488,0.001688608,0.006862709],"category_scores_gemma":[0.002044462,0.0008336476,0.001485478,0.0004835759,0.001142649,0.001426012,0.0006090433,0.003741453,0.001268804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000925201,"about_ca_system_score_gemma":0.001618886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009571735,"about_ca_topic_score_gemma":0.003578214,"domain_scores_codex":[0.999272,0.000446137,0.0000320932,0.0001270975,0.00003451159,0.0000881133],"domain_scores_gemma":[0.9990332,0.0001985649,0.0002367418,0.00008985027,0.00005461067,0.0003869186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9697413,0.009053942,0.0007048944,0.0003679045,0.0005695155,0.00004446328,0.00006777623,0.000543998,0.002697753,0.0001719157,0.001639802,0.01439658],"study_design_scores_gemma":[0.9551604,0.04274408,0.0006104892,0.00002191612,0.0002193945,0.00003540425,0.00002188105,0.0002930851,0.0002257513,0.0001668742,0.0004926987,0.000008024709],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777321,0.004656398,0.001134961,0.00177888,0.0008467453,0.00842031,0.001871384,0.0002009952,0.003358259],"genre_scores_gemma":[0.9760638,0.002719359,0.00335384,0.002447557,0.0004206618,0.008204737,0.002054411,0.00005873304,0.004676912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006862709,"threshold_uncertainty_score":0.02295804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04035846930959511,"score_gpt":0.3715122906804209,"score_spread":0.3311538213708257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}